[Cancer treatment-induced nephrotoxicity: BCR-Abl and VEGF inhibitors].
Rollino
Cristiana
C
Nefrologia, Ospedale S.G. Bosco, Torino, Italy. cristiana.rollino@libero.it
D000970:Antineoplastic Agents / Q000009:adverse effects*; D016044:Fusion Proteins, bcr-abl / Q000037:antagonists & inhibitors*; D006801:Humans; D007674:Kidney Diseases / Q000139:chemically induced*; D011505:Protein-Tyrosine Kinases / Q000037:antagonists & inhibitors*; D042461:Vascular Endothelial Growth Factor A / Q000037:antagonists & inhibitors*
D000970:Antineoplastic Agents; D042461:Vascular Endothelial Growth Factor A; D011505:Protein-Tyrosine Kinases; D016044:Fusion Proteins, bcr-abl